Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Inclusion Criteria:

Only the patients who meet all these criteria can be enrolled in the study:

* Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere.
* Gross total resection or partial resection (imaging) \>70%.
* At least be capable to obtain a tissue sample for MGMT analysis during surgery.
* Chemo-radiotherapy to be expected from Week 5 (Day 29) after surgery.
* Age \>=18 and \<=70 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
* Life expectancy \>=9 months.
* Laboratory test values must satisfy the following criteria:

  * absolute neutrophil count \>=1.5 x 10\^9/L;
  * platelet count \>=100 x 10\^9/L;
  * hemoglobin \>=80 g/L;
  * blood urea nitrogen and creatinine \< 1.5 x upper limit of normal value (ULN);
  * total bilirubin and direct bilirubin \< 1.5 x ULN;
  * alanine aminotransferase and aspartate aminotransferase \< 3 x ULN;
  * alkaline phosphatase \< 2 x ULN.
* Patients must be willing to provide written informed consent.
* Patients of child-bearing potential (including female subjects and the female partners of male subjects) must use an effective method of contraception.

Exclusion Criteria:

Patients will not be enrolled if any of the following criteria apply:

* Patient with previous or current malignancies (except melanoma) at other sites, unless disease free for at least 3 years.
* Patient who received chemotherapy, radiotherapy for study indication, or other medications for antitumor indication prior to surgery.
* Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri).
* Patient with metastatic lesions at the subtentorial or outside of calvaria.
* Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor.
* Patient who received radiotherapy at head or neck which leads to radiotherapy domain overlapping.
* Patient with acute infections requiring intravenous antibiotics.
* Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction).
* Known human immunodeficiency virus (HIV)-positive or acquired immune deficiency syndrome (AIDS)-related illness.
* Woman who is pregnant or breastfeeding.
* Patient with a history of hypersensitivity to temozolomide or other analogic alkylating agents.
* Patient with any other conditions under which investigators think the subject is not suitable for enrolment, such like having known that the subject may not have good compliance.